RT Journal Article
T1 Antivirals for influenza-like illness? a randomised controlled trial of clinical and cost effectiveness in primary carE (ALIC4 E): the ALIC4 E protocol
A1 Bongard, Emily
A1 Van der Velden, Alike W.
A1 Cook, Johanna
A1 Saville, Ben
A1 Beutels, Philippe
A1 Aabenhus, Rune Munck
A1 Brugman, Curt
A1 Chlabicz, Slawomir
A1 Coenen, Samuel
A1 Colliers, Annelies
A1 Davies, Melanie
A1 De Paor, Muireann
A1 De Sutter, An
A1 Francis, Nick A.
A1 Glinz, Dominik
A1 Godycki-ćwirko, Maciek
A1 Goossens, Hermann
A1 Holmes, Jane
A1 Ieven, Margareta
A1 De Jong, Menno
A1 Lindbaek, Morten
A1 Little, Paul
A1 Martinón Torres, Federico
A1 Moragas, Ana
A1 Pauer, József
A1 Pfeiferová, Markéta
A1 Radzeviciene-Jurgute, Ruta
A1 Sundvall, Pär-Daniel
A1 Torres, Antoni
A1 Touboul, Pia
A1 Varthalis, Dionyssios
A1 Verheij, Theo
A1 Butler, Christopher C.
K1 Pandemic influenza
K1 Antivirals
K1 Europe
K1 ALIC4 E protocol
K1 Influenza
K1 Retroviral
AB Effective management of seasonal and pandemic influenza is a high priority internationally. Guidelines in many countries recommend antiviral treatment for older people and individuals with comorbidity at increased risk of complications. However, antivirals are not often prescribed in primary care in Europe, partly because its clinical and cost effectiveness has been insufficiently demonstrated by non-industry funded and pragmatic studies
PB BMJ
SN 2044-6055
YR 2018
FD 2018
LK http://hdl.handle.net/10347/22175
UL http://hdl.handle.net/10347/22175
LA eng
NO Bongard E, van der Velden AW, Cook J, et al. Antivirals for influenzaLike Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC4  E): the ALIC4  E protocol. BMJ Open 2018;8:e021032. doi:10.1136/ bmjopen-2017-021032
NO In addition to the authors, we would like to acknowledge the contribution of the other members of the 21 ALIC4E co-ordinating centres: Bohumil Seifert, Lars Bjerrum, Mike Moore, Christos Lionis, Katalin Bezzegh, Tom Fahey, Florian Nicula, Carl Llor, Heiner Bucher, Sabine de Weirdt, Jane Barnett, Nicola Blakey, Pascale Bruno, Christine Pintaric, Bernadett Kovács, Réka Pauer, Dovile Narvilaite, Nicolay Jonassen Harbin, Anna Gryko, Basia Pytel, Ania Kowalczyk, Anca Balan, Monica Groza, Patricia Fernandez-Vandellos, Carmen Rodriguez-tenreiro Sanchez, Rosa Morros, Helena Pera, Anna Garcia Sangenis, Sofia Sundvall, Filothei Voltyraki, Irene Vasilaki, Antonios Bertsias and Ioanna Tsiligianni. We also acknowledge and thank the hard work and dedication of all the networks recruitment teams, practices and local laboratories. The authors would like to acknowledge the contribution of the Trial Steering Committee members, namely Patrick Bindels, Gordon Taylor, Åke Örtqvist and Keith Shankland (patient/public representative) and the Independent Data Monitoring Committee members Deborah Ashby, Sonia Saxena and Simon Gates. Also all the members of the Patient and Public Involvement group who contributed to the study design and development. The authors would also like to acknowledge the other members of the collaborative PREPARE work packages, in particular: Nina Gobat and Micaela Gal (WP1); Mandy Kuijstermans, Pieter Moons and Veronique Nussenblatt (WP7) and Frank Leus, Joost Schotsman and Susan van Hemert (WP8). Finally, we acknowledge the help and support from the Nuffield Department of Primary Care Health Sciences and Primary Care Clinical Trials Unit, University of Oxford in particular Sonya Beecher and Julie Allen for their respective administrative and trial management support
DS Minerva
RD 28 abr 2026